Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2026)

Precision Biosciences (DTIL) has reported Accumulated Expenses for 9 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 11.28% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 11.28% YoY), while the FY2025 annual figure was $4.7 million, down 8.39% from the prior year.
• Accumulated Expenses retreated to $1.1 million in Q1 2026 per DTIL's latest filing, from $4.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.2 million in Q3 2022 and bottomed at $1.1 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $3.4 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses grew 19.74% — and 2023, when it sank 38.05%.
• Precision Biosciences' Accumulated Expenses stood at $5.1 million in 2022, then dropped by 2.47% to $5.0 million in 2023, then increased by 4.1% to $5.2 million in 2024, then fell by 8.39% to $4.7 million in 2025, then sank by 75.98% to $1.1 million in 2026.
• Business Quant data shows DTIL's Accumulated Expenses at $1.1 million in Q1 2026, $4.7 million in Q4 2025, and $3.2 million in Q3 2025.